VJET earnings analysis
10-Q · Filed November 16, 2026 · Our reading of the company's report
The latest report
FLYTE generated $1.838 million of Q3 revenue and a 17.6% gross margin, but the company remained deeply loss-making, with a $15.121 million net loss and a $10.156 million nine-month operating cash burn. The strategic…
Read full summary
FLYTE generated $1.838 million of Q3 revenue and a 17.6% gross margin, but the company remained deeply loss-making, with a $15.121 million net loss and a $10.156 million nine-month operating cash burn. The strategic shift away from VIVO and LockeT resulted in a $12.5 million impairment and a $13.268 million discontinued-operations loss. Liquidity is the central issue: management says $1.5 million of cash as of November 10, 2026 is insufficient, substantial doubt exists about going-concern status, and potential preferred-stock conversions create extreme dilution.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
What stood out
-
FLYTE adds $1.8 million of revenue
Q3 2026 revenue was $1.838 million versus $0 in Q3 2025, entirely reflecting the FLYTE acquisition. Gross profit was $0.324 million, implying a 17.6% gross margin, while cost of revenues was $1.514 million.
-
Nine-month aviation revenue reaches $2.8 million
Nine-month revenue increased to $2.771 million from $0, while nine-month gross profit was $0.347 million. Management attributed both increases to the acquisition of FLYTE, whose results were included for approximately seven months.
-
Operating losses widened despite new revenue
Q3 loss from continuing operations was $1.853 million versus $1.235 million in Q3 2025, and SG&A increased to $2.780 million from $1.191 million. The resulting operating loss before other separately presented items was approximately $2.456 million, or a -133.6% operating margin.
-
Medical-device exit produces major impairment
The company recognized a noncash impairment loss of approximately $12.5 million on the VIVO and LockeT disposal group, driving Q3 discontinued-operations loss to $13.268 million versus $1.109 million in Q3 2025.
-
Financing temporarily offsets cash burn
Nine-month financing cash flow was $13.328 million, including $16.3 million of net equity proceeds, versus $5.037 million in the prior-year period. This financing more than offset $10.156 million of operating cash burn and contributed to a $2.305 million increase in cash during the period.
-
Liquidity remains critically constrained
Management reported $2.4 million of cash and cash equivalents at September 30, 2026, and $1.5 million of cash on November 10, 2026. The company expects operating losses and negative operating cash flows to continue and concluded that substantial doubt exists regarding its ability to continue as a going concern.
What to watch
-
Going-concern risk and funding shortfall
Management concluded there is substantial doubt about the company’s ability to continue as a going concern for one year after issuance of the financial statements. Cash on hand was $1.5 million as of November 10, 2026, while nine-month operating cash use was $10.156 million.
-
Past-due and near-term debt obligations
The company had a $5.0 million promissory note issued to Creatd, notes payable to related parties that matured in July 2026 and remained outstanding, and Assumed Notes from the FLYTE acquisition that were past due. Management states that additional capital is required over the next twelve months to fund operations and debt service.
-
Extreme potential equity dilution
Outstanding convertible preferred stock could convert into approximately 96.042 million common shares, compared with 14.392 million common shares outstanding as of August 10, 2026. The filing says this represents approximately 6,673% of existing shares and could reduce existing holders to less than 13.0% of post-conversion shares.
-
Further contingent dilution remains possible
Investors may purchase up to $70.179 million of additional Series C-4 Preferred Stock. Assuming issuance and conversion at $0.023, the additional shares could total approximately 305.126 million, and total potential conversion shares could reach approximately 401.168 million.
-
Dependence on a small leased fleet
Substantially all continuing-operations revenue is generated by Hops using a small fleet of Cirrus Vision Jets leased from SEG Jets, with remaining lease terms of approximately 11 to 19 months. Management states that the loss or extended maintenance downtime of even one aircraft could materially reduce revenue.
-
Aviation cost and regulatory exposure
The filing newly emphasizes aviation execution risks following the FLYTE acquisition, including reliance on the FAA Part 135 certificate held by Ponderosa Air, qualified pilot availability, aviation fuel costs and third-party operator capacity. Management observed continuing higher third-party aircraft operator costs, which could pressure short- and long-term margins.
Management's outlook
No explicit numeric revenue or EPS guidance was provided. Management expects operating losses and negative operating cash flow to continue, states that $1.5 million of cash on hand as of November 10, 2026 will not be sufficient to fund current operations, and estimates additional capital will be required over the next twelve months.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every VJET trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.